medigraphic.com
ISSN 1405-1710 (Impreso)

2006, Número 3

<< Anterior Siguiente >>

Rev Cent Dermatol Pascua 2006; 15 (3)


Dermatomiositis clásica. Presentación de dos casos clínicos

López L, Martínez V, Ramos GA, Arias GAC, Champet LAM

Idioma: Español
Referencias bibliográficas: 19
Paginas: 206-216
Archivo PDF: 189.13 Kb.


RESUMEN

La dermatomiositis es una enfermedad sistémica de origen desconocido cuyas principales manifestaciones son debilidad muscular y alteraciones cutáneas. El pico de incidencia es en la quinta y sexta décadas de la vida. El diagnóstico sospechado clínicamente se confirma con las enzimas musculares séricas, la electromiografía y la biopsia muscular. La mayoría de los pacientes responden a los corticosteroides.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Londoño AM. Dermatomiositis. Piel 2005; 6: 174-182.

  2. Kovacs S, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39: 899-920.

  3. Sontheimer RD, Costner MI. Dermatomyositis. Freedberg I, Eisen A, Wolf K, Arsten K, Goldsmith L, Katz S, et al, editors. Fitzpatrick´s Dermatology in General Medicine. 6th ed. Mc Graw-Hill, 2003; p.1694-1707.

  4. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7.

  5. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 403-7.

  6. Hachulla E. Dermatomyositis and polymyositis: clinical aspects and treatment. Ann Med Intern 2001; 152: 455-64.

  7. Gallais V, Crickx B, Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996; 123: 722-6.

  8. Leon G, Blancas F. Dermatomiositis. PAC Dermatología, 1a ed. Intersistemas, 2001:21-24.

  9. Parodi A, Caproni M, Marzano AV et al. Dermatomyositis in 132 patients with different clinical subtypes; cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 2002; 82: 48-51.

  10. Hann T, Newman E. Juvenile dermatomyositits. A retrospective review of 30 year experience. J Am Acad Dermatol 2001; 45: 28-34.

  11. Sontheimer R. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46: 626-36.

  12. Caproni M, Cardinali C et al. Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol 2002; 138: 23-7.

  13. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymiositis: a case-control study. Br J Dermatol 2001; 144: 825-31.

  14. Hill CL, Zhang Y et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population–based study. Lancet 2001; 357: 96-100.

  15. Dalakas M, Honfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362: 971-82.

  16. Dalakas Mc, Illa I et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment of Dermatomyositis. N Engl J Med 1993; 329: 1993-2000.

  17. Peake MF, Perkins P et al. Cutaneous ulcers of refractory polymyositis responsive to intravenous immunoglobulin. Cutis 1998; 62: 89-93.

  18. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an affective corticosteroid-sparing gent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36: 67-71.

  19. Ichiki Y, Akiyama T et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144: 894-7.




2020     |     www.medigraphic.com